334 related articles for article (PubMed ID: 19647176)
1. Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma.
Meléndez-Alafort L; Nadali A; Zangoni E; Banzato A; Rondina M; Rosato A; Mazzi U
Nucl Med Biol; 2009 Aug; 36(6):693-701. PubMed ID: 19647176
[TBL] [Abstract][Full Text] [Related]
2. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
[TBL] [Abstract][Full Text] [Related]
3. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
4. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
[TBL] [Abstract][Full Text] [Related]
5. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
[TBL] [Abstract][Full Text] [Related]
6. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.
Moustapha ME; Ehrhardt GJ; Smith CJ; Szajek LP; Eckelman WC; Jurisson SS
Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Coradini D; Zorzet S; Rossin R; Scarlata I; Pellizzaro C; Turrin C; Bello M; Cantoni S; Speranza A; Sava G; Mazzi U; Perbellini A
Clin Cancer Res; 2004 Jul; 10(14):4822-30. PubMed ID: 15269158
[TBL] [Abstract][Full Text] [Related]
8. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection.
Luo TY; Hsieh BT; Wang SJ; Lin WY; Lee TW; Shen LH; Su MJ
Nucl Med Biol; 2004 Jul; 31(5):671-7. PubMed ID: 15219287
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours.
Lambert B; Bacher K; Defreyne L
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):305-10. PubMed ID: 19521309
[TBL] [Abstract][Full Text] [Related]
12. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats.
Bao A; Goins B; Klipper R; Negrete G; Phillips WT
J Nucl Med; 2003 Dec; 44(12):1992-9. PubMed ID: 14660726
[TBL] [Abstract][Full Text] [Related]
13. [Radiotherapy with (186)Re-lipiodol II for primary liver cancer patients].
Shi L; Zhang Z; Zhuang D; Cheng H; Gao Y; Wu M
Zhonghua Wai Ke Za Zhi; 2002 Nov; 40(11):814-6. PubMed ID: 12487852
[TBL] [Abstract][Full Text] [Related]
14. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.
Knapp FF; Beets AL; Guhlke S; Zamora PO; Bender H; Palmedo H; Biersack HJ
Anticancer Res; 1997; 17(3B):1783-95. PubMed ID: 9179235
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.
Ferro-Flores G; Arteaga de Murphy C
Adv Drug Deliv Rev; 2008 Sep; 60(12):1389-401. PubMed ID: 18547675
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.
Bernal P; Raoul JL; Vidmar G; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Stare J; Buscombe J; Minh CT; Saw MM; Chen S; Ogbac R; Padhy AK
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1448-55. PubMed ID: 17692473
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models.
Miao Y; Owen NK; Fisher DR; Hoffman TJ; Quinn TP
J Nucl Med; 2005 Jan; 46(1):121-9. PubMed ID: 15632042
[TBL] [Abstract][Full Text] [Related]
18. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model.
Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC
J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730
[TBL] [Abstract][Full Text] [Related]
19. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil.
Kumar A; Srivastava DN; Bal C
J Vasc Interv Radiol; 2006 Jan; 17(1):157-61. PubMed ID: 16415146
[TBL] [Abstract][Full Text] [Related]
20. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals.
Kostarelos K; Emfietzoglou D
Anticancer Res; 2000; 20(5A):3339-45. PubMed ID: 11062762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
